glp 1 drugs and gastroparesis How Dangerous Is Gastroparesis? Glucagon-Like Peptide-1 Receptor Agonists in

We have eagerly awaited seeing the actual results since the sponsor company (Novo Nordisk) issued a press release in August that proclaimed a 20% relative reduction of cardiovascular death, heart attack or stroke, the primary endpoint of the trial

Incretin-based multi-agonist peptides are neuroprotective and anti-inflammatory in cellular models of neurodegeneration

Abstract Purpose of Review The purpose of this review is two-fold: (1) to discuss a case report of idiopathic intracranial hypertension (IIH) after abrupt cessation of a glucagon-like peptide-1 (GLP-1) receptor agonist with resultant rapid weight gain and (2) to review the literature regarding the potential role of GLP-1 receptor agonists in the treatment of IIH as well as potential pitfalls

Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease

Proposed mechanisms include physical compression of vessels and nerves, induction of glomerular hyperfiltration (48), and activation of the RAAS as well as stimulation of inflammation by local release of cytokines (49)